# Management of Adverse Effects from High-Dose Insulin Therapy in Calcium Channel Blocker/Beta-blocker Overdose: An Observational Study



Vincent Mainella, PharmD Candidate, Victoria Stevens, PharmD, BCCCP University of Colorado- Skaggs School of Pharmacy

### Background

- CCB and BB toxicities are associated with a high risk of mortality
- High-dose insulin (HDI) infusion added to standard vasopressors lead to improved outcomes
- The adverse effects of HDI and its supportive care remain incompletely characterized by extant clinical study data

# **Objective**

 Describe the adverse effects associated with HDI and supportive dextrose infusion

### Methods

- Retrospective chart reviews of patients with that received high-dose insulin
- Patients needed to have suspected CCB/BB overdose
- Patient characteristics we deemed relevant to dosing requirements were collected. Total fluid accumulation was considered the primary outcome of interest

# Results

					Lowest		Duration of			Max				
	Length of				Potassium		Dextrose		# of	Insulin				
	Stay			Accumulation	Value		Infusion	Dextrose	Hypoglycemia					Patient
s) Mortality	(days)	CRRT	ECMO	(L)	(mEq/L)	Hypokalemia	(days)	used	Incidences	(u/kg/hr)	Diabetes	ccb/bb	Age	Number
Υ	3	Υ	VA	2.9	2.1	2	0.75	D10	0	1.5	Υ	Verapamil	42	1
								D20						
								D25						
N	41	Y	N	-7.6	N/A	0	12.5	D50	7	12	N	Amlodipine	36	2
								D10						
Υ	47	Υ	VA	12.7	1.4	17	5	D20	1	11	N	Atenolol	57	3
								D10						
N	56	N	VA	8.4	2.6	6	4.5	D20	20	15	N	Propranolol	36	4
Υ	1	Υ	N	12.8	2.5	2	11	D20	0	20	N	Verapamil	44	5
								D10						
<u> </u> N	14	Υ	N	11.4	2.4	1	6	D50	0	10	N	Verapamil	35	6
								D10						
Y	0.5	Υ	N	12.8	2.9	2	0.33	D20	1	24	N	Verapamil	50	7
								D10						
N	42	Y	N	21.9	2.6	2	3.25	D20	6	4	Υ	Verapamil	48	8
								D10						
								D20						
N	9	Υ	N	9.8	2.8	7	4	D50	8	10	N	Verapamil	44	9
Y	5.5	Υ	VA	4.8	2.6	3	22	D10	0	1	Υ	Unknown	48	10
5	0.5 42	Y	N N	11.4 12.8 21.9	2.4 2.9 2.6 2.8	2 2 7	6 0.33 3.25	D10 D50 D10 D20 D10 D20 D10 D20 D50	6	24 4 10	N Y	Verapamil Verapamil Verapamil	50 48 44	7 8 9

# 1.8 (IQR: O.9-2.8) Median Portrose Duration (IQR: 3.4-9.8) Median Fluid Accumulation (IQR: 5.7-12.8)

### **Conclusions**

- Most patients will experience at least one side effect as a result of HDI+dextrose infusion
- HDI treatment for CCB/BB therapy places patients at high risk of fluid overload
- Insulin resistance may affect the maximum rate of insulin infusion

## **Implications**

- Further studies should investigate optimal HDI+dextrose treatment approaches as they relate to fluid accumulation
- The effects of insulin resistance in HDI recipients warrants further exploration

#### References

- Cole JB, Arens AM, Laes JR, Klein LR, Bangh SA, Olives TD. High dose insulin for beta-blocker and calcium channel-blocker poisoning. The American journal of emergency medicine 2018;36:1817-24.
- Lheureux PE, Zahir S, Gris M, Derrey A-S, Penaloza A. Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Critical Care 2006;10:1-6.
- Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual report of the American Association of Poison control centers' National Poison Data System (NPDS): 36th annual report. Clinical toxicology 2019;57:1220-413.

### **Disclosures**

None